News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlycoMimetics, Inc. (GLYC) Announces Presentation Of Data On Rivipansel (GMI-1070) In Combination With Current FDA-Approved Treatment For Sickle Cell Disease


4/14/2014 9:45:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that data for its lead clinical drug candidate, rivipansel (GMI-1070), was highlighted via one oral presentation and one poster at the 8th Annual Sickle Cell Disease Research and Educational Symposium and 37th National Sickle Cell Disease Scientific Meeting, held April 11-14, 2014, at the InterContinental Miami.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES